Surrogate Markers in Antiangiogenesis Clinical Trials
Author Information
Author(s): Davis D W, McConkey D J, Abbruzzese J L, Herbst R S
Primary Institution: The University of Texas MD Anderson Cancer Center
Hypothesis
The study investigates the effectiveness of surrogate markers in evaluating antiangiogenic therapies in clinical trials.
Conclusion
The study emphasizes the need for new methods and surrogate markers to assess the optimal biological dose of antiangiogenic agents.
Supporting Evidence
- Angiogenesis inhibitors are cytostatic rather than cytotoxic.
- Optimal doses for antiangiogenic agents are often below the maximum tolerated dose.
- New biological markers are needed to evaluate the effectiveness of antiangiogenic therapies.
Takeaway
This study looks at how doctors can measure the effects of cancer treatments that stop blood vessels from growing, which helps tumors grow.
Methodology
The study reviews various methods for measuring the effects of antiangiogenic therapies, including serum, plasma, urine assays, and tumor biopsy analyses.
Limitations
The study notes that many surrogate markers have not been validated and that results can vary significantly between different tumor types.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website